Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.32 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.32 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609232 | 0.91 | CETP (0.36) | CETPFOLH1HPGDGPR52ALDH1A1 | |
| SCHEMBL7605208 | 0.83 | ALDH1A1 (0.34) | CETPFOLH1SLC16A3SLC16A1MCTS1 | |
| SCHEMBL8423445 | 0.79 | PGK1 (0.33) | CETPFOLH1HPGDGAATSHR | |
| SCHEMBL7611446 | 0.79 | PTPN1 (0.45) | CETPSMN1; SMN2GAA | |
| SCHEMBL7614098 | 0.78 | FDPS (0.43) | ALDH1A1HIF1A | |
| SCHEMBL5059999 | 0.77 | FOLH1 (0.38) | CETPFOLH1ALDH1A1MMP1 | |
| SCHEMBL7606682 | 0.75 | MMP1 (0.35) | CETPMMP1 | |
| SCHEMBL7611154 | 0.74 | ACP3 (0.42) | CETPHPGDALDH1A1 | |
| SCHEMBL7606131 | 0.74 | HPGD (0.33) | CETPHPGDGPR52ALDH1A1SMN1; SMN2 | |
| SCHEMBL7607525 | 0.73 | MMP1 (0.37) | HPGDSMN1; SMN2HIF1AMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002515040-A | — | — | 2002-05-21 | — | — | JP | claimed |
| JP-2002514160-A | — | — | 2002-05-14 | — | — | JP | claimed |
| JP-2002514184-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | claimed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | claimed |
| EP-0936914-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-08-25 | — | — | EP | claimed |
| EP-0936914-A4 | — | — | 1999-08-25 | — | — | EP | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| WO-1997048400-A1 | HYDROXY-PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| US-6046180-A | NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 2000-04-04 | — | — | US | disclosed |
| EP-0954295-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1997048409-A1 | METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | disclosed |